country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-189119

Copy Link Print Information

NMI-1182

NMI-1182 is a nitric oxide-releasing prodrug of Naproxen (HY-15030). NMI-1182 is an orally active COX-1 and COX-2 inhibitor. NMI-1182 inhibits constitutive COX-1-mediated and inducible COX-2-mediated prostaglandin synthesis. NMI-1182 induces nitric oxide donor release, activating soluble guanylate cyclase to synthesize cGMP, causing vasodilation. NMI-1182 can be used for research on inflammation and pain.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 646509-43-5
Formel: C₁₇H₁₈N₂O₉
Molecular Weight:394.33

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

NMI-1182 Chemical Structure

CAS. Nr.: 646509-43-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[1]^[2]

COX-1

COX-2

Alle COX Isoform-spezifische Produkte anzeigen :

In Vitro

NMI-1182 inhibits COX-1 and COX-2 in human whole blood^[1].
NMI-1182 is a potent NO donor in LLC-PK1 cells, inducing cGMP at concentrations as low as 3 nM^[1].
NMI-1182 inhibits COX-1 and COX-2 activity in human whole blood, with −log IC₅₀ values of 4.71 and 5.05 for COX-1 and COX-2, respectively^[2].
NMI-1182 (70 μM; 15 min) induces cGMP synthesis in human hepatocytes^[1].
NMI-1182 (1 nM-10 µM) produces concentration-dependent vasodilation in isolated rat aorta^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

NMI-1182 (10 mg/kg; oral; single administration 1 h before Carrageenan (HY-125474)) exhibited anti-inflammatory activity in Carrageenan-induced paw edema rats^[2].
NMI-1182 (5 mg/kg; oral; single administration 1 h before Carrageenan injection) significantly reduced leukocyte infiltration and decreased PGE₂ levels by 90% in Carrageenan-induced air pouch inflammation rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Sprague-Dawley rats (Male, 180-220 g, fasted)^[2]
Dosage:

10 mg/kg
Administration:

p.o.; single dose 1 h prior to Carrageenan
Result:

Showed comparable inhibition of paw oedema of between 50 and 65% at 3 h post-insult.

Animal Model:

Sprague-Dawley rats (Male, 180-220 g)^[2]
Dosage:

5 mg/kg
Administration:

p.o.; single dose 1 h prior to Carrageenan
Result:

Significantly reduced Carrageenan-induced leukocyte influx.
Significantly reduced PGE₂ levels in the exudates by 90%.

Chemical Information

CAS. Nr. 646509-43-5
Molecular Weight 394.33
Formel C₁₇H₁₈N₂O₉
SMILES

O=C(OC[C@@H](O[N+]([O-])=O)CO[N+]([O-])=O)[C@H](C1=CC2=C(C=C1)C=C(C=C2)OC)C
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Handling Instructions (2659 KB)

Verweise

[1]. Young DV, et al. A comparison of the cyclooxygenase inhibitor-NO donors (CINOD), NMI-1182 and AZD3582, using in vitro biochemical and pharmacological methods. Biochemical pharmacology. 2005 Nov 01;70(9):1343-51.

[2]. Ellis JL, et al. NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor. Inflammopharmacology. 2005;12(5-6):521-34.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

NMI-1182

Alle COX Isoform-spezifische Produkte anzeigen